AstraZeneca seeks mutual growth through open collaboration
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.27 05:08:39
가나다라
0
Announced plan to invest KRW 850 billion in 2019, which accounts for more than 30% of annual sales
Will strengthen collaboration on innovative medicines, including Imfinzi global clinical and diabetes combination development
Will focus on creating a patient-centric ecosystem...emphasizing patient support and disease awareness campaigns
Multinational pharmaceutical companies are increasingly investing in R&D in Korea’s domestic pharmaceutical industry through open innovation.
According to the Korean Research-based Pharmaceutical Industry Association (KRPIA), the total amount of R&D invested in clinical research in Korea in 2022 was KRW 817.8 billion and has been on the rise for 3 consecutive years.
AstraZeneca Korea, which recently introduced bold new drugs such as Enhertu and Imfinzi, is also aiming to create a virtuous cycle of shared growth with the domestic pharmaceutical industry through active R&D investment.
AZ invests more than 30% of sales in R&D...makes notable achievements in devel
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)